文献速递食管胃疾病与幽门螺杆菌消化道肿瘤与早癌

胃微生物群介导的胃癌免疫重塑

Gastric microbiota-mediated immune remodelling in gastric cancer.
PubMed 文献 · Gut · 2026-04-22

本综述总结胃微生物群与胃癌肿瘤微环境(TME)之间的相互作用,阐述从健康黏膜到恶性肿瘤过程中胃微生物群的功能变化,重点讨论细菌对CD8+ T细胞、巨噬细胞、树突状细胞和调节性T细胞等免疫细胞的影响,并评估微生物群与免疫检查点阻断(ICB)治疗的复杂互动及潜在微生物靶向策略。

要点

  • 胃微生物群通过免疫调节影响胃癌肿瘤微环境及肿瘤发生发展。
  • 链球菌属、乳杆菌属和拟杆菌属等对TME具有强免疫调节作用。
  • 微生物代谢物和病原体相关分子模式塑造免疫细胞浸润与检查点表达。

核心结论

  • 深入理解宿主-微生物相互作用可为胃癌精准医学和微生物靶向干预提供新途径。

研究设计与样本

  • 综述类文章,总结胃微生物群与胃癌肿瘤微环境及免疫治疗相互作用的最新认识。

主要发现

  • 从健康黏膜到恶性肿瘤,胃微生物群功能发生改变,影响CD8+ T细胞、巨噬细胞、树突状细胞和调节性T细胞等免疫细胞群体。
  • 微生物代谢物和病原体相关分子模式参与塑造免疫细胞浸润、细胞因子谱和检查点分子表达。
  • 免疫检查点阻断(ICB)在胃癌中疗效不理想,与免疫抑制性胃TME相关。

关键数值与推荐

  • 链球菌属、乳杆菌属和拟杆菌属等细菌对TME显示强免疫调节效应。
  • 潜在微生物靶向策略包括微生物群调节、益生菌补充和联合治疗,以增强抗肿瘤免疫反应和提升ICB疗效。

临床怎么用

  • 可关注微生物群调节、益生菌补充及联合治疗等策略以增强抗肿瘤免疫反应并提升ICB疗效。

局限性

  • 文中指出当前胃癌微生物研究仍存在挑战,并提出了未来方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Increasing evidence indicates that the gastric microbiota plays crucial roles in regulating the tumour microenvironment (TME), influencing gastric tumourigenesis and progression. Several bacteria, including Streptococcus, Lactobacillus and Bacteroides, have shown robust immunomodulatory effects on TME. In this review, we summarise current understanding of the crosstalk between the gastric microbiota and TME in gastric cancer (GC). Functional alterations of the gastric microbiota from healthy mucosa to malignancy are delineated, with emphasis on the impacts of bacteria on different immune cell populations in gastric tumours, such as CD8+ T cells, macrophages, dendritic cells and regulatory T cells. The immunomodulatory roles of microbial metabolites and pathogen-associated molecular patterns in shaping immune cell infiltration, cytokine profiles and checkpoint molecule expression are also explored. While immune checkpoint blockade (ICB) has emerged as a promising treatment of various cancers, its efficacy in GC remains unsatisfactory due to the immunosuppressive gastric TME. We therefore evaluate the intricate interplays between the gastric microbiota and immunotherapy, and suggest potential microbiota-targeting strategies (eg, microbiota modulation, probiotics supplementation and combination therapies) to enhance antitumour immune response and boost ICB efficacy. We conclude by highlighting current challenges and providing future directions for microbiota research in GC. Overall, a deeper understanding of host-microbe interactions can provide promising avenues for precision medicine and the development of microbiota-targeting interventions against GC.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Gao J, Lau HC, Fuhler GM, et al. Gastric microbiota-mediated immune remodelling in gastric cancer. Gut. 2026. PMID: 42020299. doi:10.1136/gutjnl-2026-338505

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。